Form 4: Integrated Biopharma Director Robert Canarick Granted 50,000 Stock Options
Insider Transaction Report
Integrated Biopharma Inc. Director Robert Canarick was granted 50,000 stock options with an exercise price of $0.3, vesting in four equal installments through June 2026.
Summary
- Robert Canarick, a Director of Integrated Biopharma Inc. (INBP), was granted 50,000 stock options.
- The stock options have an exercise price of $0.3 per share.
- The grant date for these options was June 18, 2025, and they are set to expire on June 18, 2035.
- The 50,000 stock options will vest in four equal installments of 12,500 options each.
- The vesting dates are scheduled for September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice that aligns management incentives with shareholder interests, indicating a routine corporate action without significant immediate positive or negative implications for the company's financial health.
Positives
- The grant of 50,000 stock options to Director Robert Canarick aligns his financial interests with those of the shareholders, as the options become valuable only if the company's stock price increases above the $0.3 exercise price.
Future Outlook
The document primarily details a past transaction and its future vesting schedule, indicating that the options will become exercisable in four equal installments through June 2026.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director, which is a common practice in corporate compensation structures across various industries to incentivize long-term performance and align management interests with shareholder value.
Stakeholder Impact
- Shareholders: The equity grant to a director is intended to align the director's financial incentives with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.
Next Steps
- The stock options will vest in four equal installments on September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/18/2025 | Date of stock option grant to Robert Canarick. |
| 09/30/2025 | First vesting installment of 12,500 stock options. |
| 12/31/2025 | Second vesting installment of 12,500 stock options. |
| 03/31/2026 | Third vesting installment of 12,500 stock options. |
| 06/30/2026 | Fourth and final vesting installment of 12,500 stock options. |
| 06/20/2025 | Date the Form 4 was signed by Robert Canarick. |
| 06/18/2035 | Expiration date of the granted stock options. |
Keywords
Integrated Biopharma, INBP, stock options, director compensation, Robert Canarick, SEC Form 4, beneficial ownership, equity grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.